PL3076967T3 - Metody leczenia objawów rezydualnych schizofrenii - Google Patents
Metody leczenia objawów rezydualnych schizofreniiInfo
- Publication number
- PL3076967T3 PL3076967T3 PL14867061T PL14867061T PL3076967T3 PL 3076967 T3 PL3076967 T3 PL 3076967T3 PL 14867061 T PL14867061 T PL 14867061T PL 14867061 T PL14867061 T PL 14867061T PL 3076967 T3 PL3076967 T3 PL 3076967T3
- Authority
- PL
- Poland
- Prior art keywords
- schizophrenia
- treatment
- methods
- residual symptoms
- symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911416P | 2013-12-03 | 2013-12-03 | |
| US201461925607P | 2014-01-09 | 2014-01-09 | |
| US201461975702P | 2014-04-04 | 2014-04-04 | |
| US201462032326P | 2014-08-01 | 2014-08-01 | |
| EP14867061.5A EP3076967B1 (en) | 2013-12-03 | 2014-12-03 | Methods for treating residual symptoms of schizophrenia |
| PCT/US2014/068443 WO2015085004A1 (en) | 2013-12-03 | 2014-12-03 | Novel methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3076967T3 true PL3076967T3 (pl) | 2021-12-20 |
Family
ID=53274093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14867061T PL3076967T3 (pl) | 2013-12-03 | 2014-12-03 | Metody leczenia objawów rezydualnych schizofrenii |
Country Status (17)
| Country | Link |
|---|---|
| US (8) | US9956227B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3076967B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6475727B2 (cg-RX-API-DMAC7.html) |
| KR (8) | KR102421656B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN114366741A (cg-RX-API-DMAC7.html) |
| AU (4) | AU2014360452C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016012781A2 (cg-RX-API-DMAC7.html) |
| CA (4) | CA3148303C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3076967T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2893621T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE056496T2 (cg-RX-API-DMAC7.html) |
| IL (4) | IL293523B2 (cg-RX-API-DMAC7.html) |
| MX (3) | MX395458B (cg-RX-API-DMAC7.html) |
| PL (1) | PL3076967T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3076967T (cg-RX-API-DMAC7.html) |
| RU (1) | RU2682658C1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015085004A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2679754C (en) | 2007-03-12 | 2018-08-07 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
| KR20110022631A (ko) * | 2008-05-27 | 2011-03-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물 |
| US9034911B2 (en) | 2008-10-28 | 2015-05-19 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
| MX2012004753A (es) | 2009-10-23 | 2012-09-07 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina. |
| JP5894574B2 (ja) | 2010-04-22 | 2016-03-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| US9428506B2 (en) | 2012-04-14 | 2016-08-30 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders |
| EP2968320B1 (en) | 2013-03-15 | 2020-11-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
| DK3076967T3 (da) | 2013-12-03 | 2021-10-25 | Intra Cellular Therapies Inc | Fremgangsmåder til behandling af residuelle symptomer på skizofreni |
| MX2016013046A (es) | 2014-04-04 | 2017-02-15 | Intra Cellular Therapies Inc | Compuestos organicos. |
| CN106535898A (zh) | 2014-04-04 | 2017-03-22 | 细胞内治疗公司 | 有机化合物 |
| ES2874549T3 (es) | 2015-02-27 | 2021-11-05 | Dechra Ltd | Estimulación del apetito, control de la pérdida de peso, y tratamiento de la anorexia en perros y gatos |
| WO2017011767A2 (en) * | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| WO2017117514A1 (en) * | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| CN105560192A (zh) * | 2016-01-07 | 2016-05-11 | 万全万特制药江苏有限公司 | 一种棕榈酸帕利哌酮长效微球注射液的制备方法 |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| UA125873C2 (uk) | 2016-03-10 | 2022-06-29 | Янссен Фармацевтика Нв | Спосіб лікування депресії з використанням антагоністів рецептора орексин-2 |
| IL281050B2 (en) | 2016-03-25 | 2023-04-01 | Intra Cellular Therapies Inc | A controlled or delayed release pharmaceutical preparation containing a deuterated compound |
| WO2017172784A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| JP2019510039A (ja) * | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| JP2020500875A (ja) * | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| EP3558276B1 (en) | 2016-12-20 | 2024-11-06 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
| EP3562484B1 (en) | 2016-12-29 | 2021-08-25 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders |
| US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
| RU2767410C2 (ru) | 2017-03-24 | 2022-03-17 | Интра-Селлулар Терапиз, Инк. | Новые композиции и способы |
| ES2881783T3 (es) | 2017-06-26 | 2021-11-30 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona |
| KR102667268B1 (ko) | 2017-07-26 | 2024-05-17 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| EP3658145A4 (en) | 2017-07-26 | 2021-04-21 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| US11440911B2 (en) | 2017-09-26 | 2022-09-13 | Intra-Cellular Therapies, Inc. | Salts and crystals |
| WO2019074492A1 (en) | 2017-10-10 | 2019-04-18 | Obrien Christopher F | METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS |
| KR102089737B1 (ko) | 2017-11-01 | 2020-03-16 | 한국화학연구원 | 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법 |
| JP7268026B2 (ja) | 2017-12-05 | 2023-05-02 | サノビオン ファーマシューティカルズ インク | 非ラセミ混合物およびその使用 |
| CN112236138B (zh) | 2017-12-05 | 2024-05-31 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
| EP3765021A4 (en) * | 2018-03-16 | 2022-03-09 | Intra-Cellular Therapies, Inc. | NOVEL PROCESSES |
| CN112040940A (zh) | 2018-03-23 | 2020-12-04 | 细胞内治疗公司 | 有机化合物 |
| CN112384218B (zh) | 2018-06-06 | 2024-04-26 | 细胞内治疗公司 | 盐和晶体 |
| ES3028377T3 (en) | 2018-06-08 | 2025-06-19 | Intra Cellular Therapies Inc | Fused gamma-carbolines for acute treatment of anxiety or depression |
| KR20250034203A (ko) | 2018-06-11 | 2025-03-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| WO2019243452A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| WO2019246384A1 (en) | 2018-06-21 | 2019-12-26 | Aquestive Therapeutics, Inc. | System and method for making personalized individual unit doses containing pharmaceutical actives |
| JP2022500362A (ja) | 2018-08-29 | 2022-01-04 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規組成物および方法 |
| AU2019331490B2 (en) * | 2018-08-31 | 2025-04-24 | Intra-Cellular Therapies, Inc. | Novel methods |
| CA3108553A1 (en) * | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP7637616B2 (ja) | 2018-09-07 | 2025-02-28 | アクエスティブ セラピューティクス インコーポレイテッド | 厳密な活性剤溶解プロファイルを有する口腔用フィルム組成物及び剤形 |
| IL283963B2 (en) | 2018-12-17 | 2025-01-01 | Intra Cellular Therapies Inc | Synthesis of condensed gamma-carbolines and converted heterocycles |
| BR112021011792A2 (pt) | 2018-12-17 | 2021-08-31 | Intra-Cellular Therapies, Inc. | Composto orgânico |
| US12331052B2 (en) | 2018-12-21 | 2025-06-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP7377871B2 (ja) | 2018-12-21 | 2023-11-10 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| KR20200087594A (ko) | 2019-01-11 | 2020-07-21 | 한국화학연구원 | 레티노익산을 포함하는 미립구형 서방출 제제 및 그의 제조방법 |
| EP3980009A4 (en) | 2019-06-04 | 2023-07-05 | Sunovion Pharmaceuticals Inc. | MODIFIED RELEASE FORMULATIONS AND ASSOCIATED USES |
| EP4134101A1 (en) | 2019-07-07 | 2023-02-15 | Intra-Cellular Therapies, Inc. | Deuterated lumateperone for the treatment of the bipolar ii disorder |
| WO2021062307A1 (en) | 2019-09-25 | 2021-04-01 | Intra-Cellular Therapies, Inc. | Novel methods |
| CA3159382A1 (en) | 2019-11-01 | 2021-05-06 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| KR20220126287A (ko) | 2019-11-14 | 2022-09-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 멀티모달 조성물 및 치료 방법 |
| JP7261942B2 (ja) | 2019-12-11 | 2023-04-20 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| US11344503B2 (en) * | 2019-12-13 | 2022-05-31 | Halo Science LLC | Cariprazine release formulations |
| EP4076461A4 (en) * | 2019-12-19 | 2024-01-03 | Intra-Cellular Therapies, Inc. | Methods of schizophrenia treatment |
| KR102383448B1 (ko) | 2020-04-20 | 2022-04-06 | 한국화학연구원 | 락트산 또는 글리콜산을 포함하는 미립구형 서방출 제제 및 그의 제조방법 |
| KR20230134136A (ko) | 2021-01-15 | 2023-09-20 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 전구약물 조성물 및 치료 방법 |
| US11992559B2 (en) | 2021-02-24 | 2024-05-28 | Oakwood Laboratories, Llc | Microsphere formulations comprising lurasidone and methods for making and using the same |
| WO2022192476A1 (en) | 2021-03-09 | 2022-09-15 | Aquestive Therapeutics, Inc. | Dosage forms having equivalent biocomparable profiles |
| EP4460490A1 (en) * | 2022-01-03 | 2024-11-13 | Engrail Therapeutics, Inc. | Deuterated organic compounds and uses thereof |
| KR20250012110A (ko) | 2022-05-18 | 2025-01-23 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규 방법 |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| JP2024171855A (ja) | 2023-05-30 | 2024-12-12 | 株式会社ダイセル | 樹脂組成物 |
| TW202506104A (zh) | 2023-07-02 | 2025-02-16 | 美商英格瑞治療公司 | 氘化有機化合物及其用途（一） |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
| WO2025240804A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices and methods |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
| US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
| US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
| IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| ES2058068T3 (es) | 1986-03-19 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazol-(3,2-a)-pirimidin-5-ona y compuestos fungicidas con contenido en dichos derivados. |
| ES2058069T3 (es) | 1986-04-07 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado. |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| KR100354270B1 (ko) | 1993-11-19 | 2003-02-11 | 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii | 마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸 |
| AU707748B2 (en) | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
| US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
| US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
| US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
| US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
| US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
| US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
| GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
| US6884429B2 (en) | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
| WO1999018057A1 (en) | 1997-10-06 | 1999-04-15 | Massachusetts Institute Of Technology | Preparation of diaryl ether by condensation reactions |
| US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
| EP1058678B1 (en) | 1998-02-26 | 2002-12-11 | Massachusetts Institute of Technology | Metal-catalyzed arylations and vinylations of hydrazines, hydrazones, hydroxylamines and oximes |
| US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
| US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| DK1097158T3 (da) | 1998-07-10 | 2006-05-29 | Massachusetts Inst Technology | Ligander til metaller og metalkatalyserede metoder |
| US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
| NZ512410A (en) | 1998-12-17 | 2003-02-28 | Alza Corp | Controlled release liquid filled gelatin capsules comprising barrier, expandable and superpermeable layers and an orifice |
| NO309305B1 (no) | 1999-02-19 | 2001-01-15 | Norsk Hydro As | Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater |
| US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
| AR023574A1 (es) | 1999-04-23 | 2002-09-04 | Pharmacia & Upjohn Co Llc | Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| IL147109A0 (en) * | 1999-06-15 | 2002-08-14 | Du Pont Pharm Co | Substtituted heterocycle fused gamma-carbolines |
| US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
| US6699852B2 (en) | 2000-12-20 | 2004-03-02 | Bristol-Myers Squibb Pharma Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| US6759554B2 (en) | 2001-04-24 | 2004-07-06 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| DE10123129A1 (de) | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel |
| US6849640B2 (en) | 2001-08-08 | 2005-02-01 | Pharmacia & Upjohn Company | Therapeutic 1H-pyrido [4,3-b] indoles |
| EP1314554A1 (fr) | 2001-11-23 | 2003-05-28 | Kba-Giori S.A. | Dispositif de décollage d'éléments de sécurité |
| DE10162121A1 (de) | 2001-12-12 | 2003-06-18 | Berolina Drug Dev Ab Svedala | Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel |
| ES2293039T3 (es) | 2002-07-29 | 2008-03-16 | Alza Corporation | Procedimiento y formas de dosificacion para el suministro controlado de paliperidona. |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| KR20050032107A (ko) | 2002-08-02 | 2005-04-06 | 메사추세츠 인스티튜트 오브 테크놀로지 | 구리를 촉매로 한 탄소-헤테로원자 결합 및 탄소-탄소결합 형성방법 |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| AU2003287433A1 (en) | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
| US7109339B2 (en) | 2002-12-19 | 2006-09-19 | Bristol-Myers Squibb Company | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
| NZ541146A (en) * | 2003-01-16 | 2009-04-30 | Acadia Pharm Inc | N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide, also known as ACP-103, and its tartrate salt as therapeutics for neurodegenerative diseases |
| EP1654226B1 (en) | 2003-07-21 | 2008-10-22 | SmithKline Beecham Corporation | (2s,4s)-4-fluoro-1- 4-fluoro-beta-(4-fluorophenyl)-l-phenylalanyl -2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
| AR045796A1 (es) | 2003-09-26 | 2005-11-16 | Solvay Pharm Bv | Derivados de hexa y octahidro - pirido (1,2-a) pirazina con actividad antagonista de nk1. composiciones farmaceuticas. |
| JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
| EP1756102A1 (en) | 2004-03-05 | 2007-02-28 | Pharma C S.A. | 8-PHENOXY-GammaCARBOLINE DERIVATIVES |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| CA2580619C (en) | 2004-09-20 | 2013-11-12 | Mount Sinai School Of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| JP2008513432A (ja) | 2004-09-21 | 2008-05-01 | ファイザー・プロダクツ・インク | Ｃｎｓ状態の治療に有用なｎ−メチルヒドロキシエチルアミン |
| US7614727B2 (en) | 2004-09-30 | 2009-11-10 | Fujifilm Corporation | Liquid ejection head, manufacturing method thereof, and image forming apparatus |
| MX2007006896A (es) | 2004-12-15 | 2007-06-26 | Hoffmann La Roche | Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer. |
| AU2006209216A1 (en) * | 2005-01-25 | 2006-08-03 | Galenea Corp | Substituted arylamine compounds and their use as 5-HT6 modulators |
| AU2006208201A1 (en) | 2005-01-25 | 2006-08-03 | Celgene Corporation | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione |
| WO2006123359A2 (en) * | 2005-03-01 | 2006-11-23 | Sun Pharmaceutical Industries Limited | A process of making microspheres |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| CN101309917B (zh) | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| EP1973876A2 (en) | 2006-01-13 | 2008-10-01 | Wyeth | Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
| CA2679754C (en) * | 2007-03-12 | 2018-08-07 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| AU2008282742A1 (en) | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| JP5393677B2 (ja) | 2007-08-15 | 2014-01-22 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体 |
| US20090209608A1 (en) | 2007-08-29 | 2009-08-20 | Protia, Llc | Deuterium-enriched asenapine |
| US20090076159A1 (en) | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched eplivanserin |
| NZ586963A (en) | 2008-02-05 | 2012-11-30 | Clera Inc | Use of dopamine d2 receptor inhibitors for alleviating depression or improving cognition |
| JP2011511638A (ja) | 2008-02-07 | 2011-04-14 | シェーリング コーポレイション | 抗ｔｓｌｐｒ抗体の設計製作 |
| WO2009114181A2 (en) | 2008-03-12 | 2009-09-17 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines solid |
| KR20110022631A (ko) * | 2008-05-27 | 2011-03-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물 |
| US8309772B2 (en) | 2008-07-31 | 2012-11-13 | Celanese International Corporation | Tunable catalyst gas phase hydrogenation of carboxylic acids |
| EP2349219A4 (en) * | 2008-09-29 | 2013-05-01 | Univ Mercer | BIOLOGICALLY EFFECTIVE SUBSTANCES CAPSULATING NANO BEADS AND METHOD FOR FORMULATING NANO BEADS |
| US20100159033A1 (en) | 2008-09-29 | 2010-06-24 | Auspex Pharmaceuticals, Inc. | Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor |
| US20110318415A1 (en) * | 2009-03-09 | 2011-12-29 | Chun Li | Hollow Gold Nanospheres (HAuNSs) and HAuNSs-Loaded Microspheres Useful in Drug Delivery |
| JP5894574B2 (ja) * | 2010-04-22 | 2016-03-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| AU2011343429B2 (en) | 2010-12-16 | 2016-10-20 | Sunovion Pharmaceuticals Inc. | Sublingual films |
| US9428506B2 (en) * | 2012-04-14 | 2016-08-30 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders |
| EP2895485A1 (en) | 2012-09-14 | 2015-07-22 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
| EP2968320B1 (en) * | 2013-03-15 | 2020-11-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
| DK3076967T3 (da) | 2013-12-03 | 2021-10-25 | Intra Cellular Therapies Inc | Fremgangsmåder til behandling af residuelle symptomer på skizofreni |
| CN106535898A (zh) * | 2014-04-04 | 2017-03-22 | 细胞内治疗公司 | 有机化合物 |
| MX2016013046A (es) | 2014-04-04 | 2017-02-15 | Intra Cellular Therapies Inc | Compuestos organicos. |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| EP3302442B1 (en) | 2015-06-03 | 2024-10-16 | Triastek, Inc. | Dosage forms and use thereof |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| IL281050B2 (en) * | 2016-03-25 | 2023-04-01 | Intra Cellular Therapies Inc | A controlled or delayed release pharmaceutical preparation containing a deuterated compound |
| WO2017165755A1 (en) | 2016-03-25 | 2017-09-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US11014925B2 (en) * | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| WO2018106916A1 (en) | 2016-12-07 | 2018-06-14 | Concert Pharmaceuticals, Inc. | Deuterated quinoxaline compounds |
| RU2767410C2 (ru) * | 2017-03-24 | 2022-03-17 | Интра-Селлулар Терапиз, Инк. | Новые композиции и способы |
| US11655251B2 (en) | 2017-11-27 | 2023-05-23 | Egis Gyogyszergyar Zrt. | Method for the production of lumateperone and its salts |
| JP7401442B2 (ja) * | 2018-01-31 | 2023-12-19 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| EP3765021A4 (en) * | 2018-03-16 | 2022-03-09 | Intra-Cellular Therapies, Inc. | NOVEL PROCESSES |
| JP2021519271A (ja) * | 2018-03-23 | 2021-08-10 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| JP2022500362A (ja) * | 2018-08-29 | 2022-01-04 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規組成物および方法 |
| WO2021062307A1 (en) * | 2019-09-25 | 2021-04-01 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR20250012110A (ko) * | 2022-05-18 | 2025-01-23 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규 방법 |
-
2014
- 2014-12-03 DK DK14867061.5T patent/DK3076967T3/da active
- 2014-12-03 IL IL293523A patent/IL293523B2/en unknown
- 2014-12-03 AU AU2014360452A patent/AU2014360452C1/en active Active
- 2014-12-03 CA CA3148303A patent/CA3148303C/en active Active
- 2014-12-03 CA CA3205777A patent/CA3205777A1/en active Pending
- 2014-12-03 EP EP14867061.5A patent/EP3076967B1/en not_active Revoked
- 2014-12-03 PT PT14867061T patent/PT3076967T/pt unknown
- 2014-12-03 KR KR1020217024479A patent/KR102421656B1/ko active Active
- 2014-12-03 US US15/101,874 patent/US9956227B2/en active Active
- 2014-12-03 PL PL14867061T patent/PL3076967T3/pl unknown
- 2014-12-03 KR KR1020237014108A patent/KR20230058736A/ko active Pending
- 2014-12-03 KR KR1020167017585A patent/KR102287288B1/ko active Active
- 2014-12-03 ES ES14867061T patent/ES2893621T3/es active Active
- 2014-12-03 WO PCT/US2014/068443 patent/WO2015085004A1/en not_active Ceased
- 2014-12-03 MX MX2021007665A patent/MX395458B/es unknown
- 2014-12-03 EP EP20153731.3A patent/EP3666271A1/en active Pending
- 2014-12-03 CA CA2932610A patent/CA2932610C/en active Active
- 2014-12-03 CN CN202210062907.5A patent/CN114366741A/zh active Pending
- 2014-12-03 IL IL246002A patent/IL246002B2/en unknown
- 2014-12-03 HU HUE14867061A patent/HUE056496T2/hu unknown
- 2014-12-03 KR KR1020247025920A patent/KR20240119197A/ko active Pending
- 2014-12-03 CN CN201480074647.7A patent/CN105939712A/zh active Pending
- 2014-12-03 KR KR1020217012502A patent/KR102372145B1/ko active Active
- 2014-12-03 JP JP2016536205A patent/JP6475727B2/ja active Active
- 2014-12-03 MX MX2016007219A patent/MX383855B/es unknown
- 2014-12-03 KR KR1020237003673A patent/KR102692169B1/ko active Active
- 2014-12-03 IL IL321987A patent/IL321987A/en unknown
- 2014-12-03 CA CA3148326A patent/CA3148326A1/en active Pending
- 2014-12-03 RU RU2016126445A patent/RU2682658C1/ru active
- 2014-12-03 KR KR1020217012501A patent/KR102373288B1/ko active Active
- 2014-12-03 BR BR112016012781A patent/BR112016012781A2/pt not_active Application Discontinuation
- 2014-12-03 KR KR1020227023990A patent/KR102495941B1/ko active Active
-
2016
- 2016-06-02 MX MX2022011140A patent/MX2022011140A/es unknown
-
2018
- 2018-03-12 US US15/918,955 patent/US10322134B2/en active Active
-
2019
- 2019-01-17 AU AU2019200301A patent/AU2019200301B2/en active Active
- 2019-02-01 JP JP2019016947A patent/JP6874028B2/ja active Active
- 2019-04-23 US US16/392,409 patent/US10960009B2/en active Active
- 2019-06-17 US US16/443,240 patent/US10960010B2/en active Active
- 2019-07-10 US US16/507,956 patent/US11026951B2/en active Active
-
2020
- 2020-04-03 AU AU2020202386A patent/AU2020202386C1/en active Active
-
2021
- 2021-02-12 JP JP2021021096A patent/JP7262495B2/ja active Active
- 2021-04-30 US US17/245,939 patent/US20210322433A1/en active Pending
- 2021-12-22 AU AU2021290277A patent/AU2021290277B2/en active Active
-
2023
- 2023-04-11 JP JP2023064176A patent/JP7600299B2/ja active Active
- 2023-09-17 IL IL305990A patent/IL305990B2/en unknown
- 2023-10-04 US US18/481,168 patent/US20240024334A1/en active Pending
-
2024
- 2024-12-04 JP JP2024211044A patent/JP2025032193A/ja active Pending
-
2025
- 2025-08-08 US US19/295,514 patent/US20250360140A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3076967T3 (pl) | Metody leczenia objawów rezydualnych schizofrenii | |
| IL283943A (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders | |
| LT2885010T (lt) | Tautopatijos gydymo būdai | |
| EP2968208A4 (en) | TREATMENT OF CATAPLEXIA | |
| PL3542798T3 (pl) | Aceklidyna do zastosowania w leczeniu starczowzroczności | |
| LT2981255T (lt) | Empagliflozino terapiniai panaudojimo būdai | |
| HRP20190101T1 (hr) | Terapeutske uporabe empagliflozina | |
| LT3007726T (lt) | Tautopatijos gydymo būdai | |
| DK3021838T3 (da) | Behandling af fedme | |
| PT3626270T (pt) | Tratamento de doenças cardiovasculares | |
| PT2953948T (pt) | Antagonistas de integrina fluorada | |
| HRP20182138T1 (hr) | Modificirani serpini za liječenje poremećaja s krvarenjem | |
| DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
| EP2988708A4 (en) | ANKLE SUPPORT | |
| LT3563837T (lt) | Terapija bakteriofagu | |
| EP2982331A4 (en) | Treatment tool | |
| EP2945942A4 (en) | Voriconazole IMMUNOASSAY | |
| IL242220A0 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| HRP20190219T1 (hr) | Spojevi za tretman pretilosti i postupci za njihovu uporabu | |
| EP2999799A4 (en) | METHOD FOR TREATING CARCINOMA | |
| DK2976101T3 (da) | Behandlingsfremgangsmåde | |
| EP2996772A4 (en) | Methods for the treatment of neurodegeneration | |
| DK2968606T3 (da) | Behandling af autoimmune sygdomme | |
| DK3041506T3 (da) | Behandlingsfremgangsmåde | |
| HUE042691T2 (hu) | Tiazolo-pirimidinon felhasználása gyulladásos bélbetegségek kezeléséhez |